Cargando…

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma

BACKGROUND: The development and evaluation of new therapeutic approaches for malignant mesothelioma has been sparse due, in part, to lack of suitable tumor models. METHODS: We established primary mesothelioma cultures from pleural and ascitic fluids of five patients with advanced mesothelioma. Elect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalra, Neetu, Zhang, Jingli, Thomas, Anish, Xi, Liqiang, Cheung, Mitchell, Talarchek, Jacqueline, Burkett, Sandra, Tsokos, Maria G, Chen, Yuanbin, Raffeld, Mark, Miettinen, Markku, Pastan, Ira, Testa, Joseph R, Hassan, Raffit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431029/ https://www.ncbi.nlm.nih.gov/pubmed/25952750 http://dx.doi.org/10.1186/s12885-015-1362-2

Ejemplares similares

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
por: Ghafoor, Azam, et al.
Publicado: (2021)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
por: Zhang, Yi-Fan, et al.
Publicado: (2015)

In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice
por: Feng, Mingqian, et al.
Publicado: (2011)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2017)

Distinctive clinical characteristics of malignant mesothelioma in young patients
por: Thomas, Anish, et al.
Publicado: (2015)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
por: Osmanbeyoglu, Hatice Ulku, et al.
Publicado: (2022)

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma
por: Nair, Nishanth Ulhas, et al.
Publicado: (2023)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma
por: Amelio, Ivano
Publicado: (2017)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2023)

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
por: Barnett, Sarah E., et al.
Publicado: (2023)

Phenotypic stability and metastatic behaviour of serially xenografted rat mesotheliomas.
por: Edwards, R. E., et al.
Publicado: (1990)

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
por: Tomar, Sakshi, et al.
Publicado: (2022)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
por: Andrici, Juliana, et al.
Publicado: (2015)

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
por: Singh, Anita, et al.
Publicado: (2022)

CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2023)

Mesothelioma
por: Rao, Nagarjun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k3h7plutpc1c4k6h1pb17oa7e7